Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure
This article was originally published in Scrip
Executive Summary
Pfizer, Janssen and Elan are to end all clinical trials with intravenous bapineuzumab in the treatment of mild-to-moderate Alzheimer's disease. The decision came after the monoclonal antibody, which targets amyloid-beta protein, did not meet the co-primary endpoints of change in cognitive and functional performance in a Janssen-led Phase III clinical trial (Study 301) with patients without the apolipoprotein E epsilon 4 (ApoE4) gene mutation.
You may also be interested in...
Prothena Sees Potential In Targeting Amyloid, Validated By Biogen
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.